TY - GEN
T1 - Profile of Diabetes Mellitus Therapy in COVID-19 Patients with Diabetes Mellitus in Kogabwilhan II Emergency Hospital Surabaya
AU - Gayatri, Ni Putu Ayu Deviana
AU - Hasmono, Didik
AU - Triyono, Erwin Astha
AU - Jaya, Halim Priyahau
AU - Parambang, Sandra Junita
N1 - Publisher Copyright:
© 2023 American Institute of Physics Inc.. All rights reserved.
PY - 2023/11/21
Y1 - 2023/11/21
N2 - Diabetes mellitus is common comorbidity found in COVID-19 patients, increasing the severity of clinical symptoms and mortality rate. Several studies found that reasonable glycemic control significantly improved the clinical outcomes in diabetic COVID-19 patients. Regular blood glucose monitoring followed by optimal use of antidiabetic therapy is one of the solutions. The aims of this study are to analyze patient characteristics, clinical symptoms, the profile of diabetes mellitus therapy, and the length of hospital stay of COVID-19 patients with diabetes mellitus at KOGABWILHAN II Emergency Hospital Surabaya on May-December 2020. This study uses a cross-sectional analytic design. A total of 106 patients was enrolled in this study. Demographic data, clinical characteristics, length of hospital stay, and therapy profile are presented in tables and graphs. Data analysis was performed using SPSS version 25. The correlation analysis using the Chi-Square and Spearman test; the differences between variables were analyzed using the Mann-Whitney U test. Most of the patients in this study (61.32%) experienced mild symptoms such as productive cough (33.02%), nonproductive cough (16.04%), and headache (13.21%). The two most common antidiabetic were glimepiride (14.15%) and a combination of insulin detemir + insulin glulisine (2.83%). Based on analysis of 64 patients, the combination of glimepiride (1x2mg) + Metformin 500 mg (2x500 mg) PO had the shortest median rate of change in fasting blood glucose (2 days), with a median length of hospital stay eight days. Most of the patients in this study (44.34%) did not meet the therapy goal of post-therapy FBG <130 mg/dL. Almost half of the patients in this study were hospitalized for 6-10 days (49.06%). We conclude that the treatment of diabetes mellitus in this study did not achieve the expected therapeutic outcomes, and further research is needed to obtain better diabetes treatment management in COVID-19 patients.
AB - Diabetes mellitus is common comorbidity found in COVID-19 patients, increasing the severity of clinical symptoms and mortality rate. Several studies found that reasonable glycemic control significantly improved the clinical outcomes in diabetic COVID-19 patients. Regular blood glucose monitoring followed by optimal use of antidiabetic therapy is one of the solutions. The aims of this study are to analyze patient characteristics, clinical symptoms, the profile of diabetes mellitus therapy, and the length of hospital stay of COVID-19 patients with diabetes mellitus at KOGABWILHAN II Emergency Hospital Surabaya on May-December 2020. This study uses a cross-sectional analytic design. A total of 106 patients was enrolled in this study. Demographic data, clinical characteristics, length of hospital stay, and therapy profile are presented in tables and graphs. Data analysis was performed using SPSS version 25. The correlation analysis using the Chi-Square and Spearman test; the differences between variables were analyzed using the Mann-Whitney U test. Most of the patients in this study (61.32%) experienced mild symptoms such as productive cough (33.02%), nonproductive cough (16.04%), and headache (13.21%). The two most common antidiabetic were glimepiride (14.15%) and a combination of insulin detemir + insulin glulisine (2.83%). Based on analysis of 64 patients, the combination of glimepiride (1x2mg) + Metformin 500 mg (2x500 mg) PO had the shortest median rate of change in fasting blood glucose (2 days), with a median length of hospital stay eight days. Most of the patients in this study (44.34%) did not meet the therapy goal of post-therapy FBG <130 mg/dL. Almost half of the patients in this study were hospitalized for 6-10 days (49.06%). We conclude that the treatment of diabetes mellitus in this study did not achieve the expected therapeutic outcomes, and further research is needed to obtain better diabetes treatment management in COVID-19 patients.
UR - http://www.scopus.com/inward/record.url?scp=85179606065&partnerID=8YFLogxK
U2 - 10.1063/5.0128263
DO - 10.1063/5.0128263
M3 - Conference contribution
AN - SCOPUS:85179606065
T3 - AIP Conference Proceedings
BT - AIP Conference Proceedings
A2 - Warid, Muhammad Nabil Mohd
A2 - Khan, Muhammed Abdullah Al Sayem
PB - American Institute of Physics Inc.
T2 - 1st Technology and Policy for Supporting Implementation of COVID-19 Response and Recovery Plan in Southeast Asia, ITTP-COVID19 2021
Y2 - 6 August 2021 through 8 August 2021
ER -